Recent years have witnessed groundbreaking progresses in the field of diabetes treatment, with a particular focus on GLP-1 receptor agonists. Among these novel therapies, retatrutide and trizepatide are emerging as https://denisnobj268686.aioblogs.com/91638281/novel-therapeutic-targets-in-diabetes-retatrutide-and-trizepatide